Literature DB >> 23847363

Sorafenib makes headway on metastatic thyroid cancer.

.   

Abstract

In a randomized phase III clinical trial, patients with metastatic differentiated cancer of the thyroid who were treated with sorafenib achieved median progression-free survival of 10.8 months, compared with 5.8 months among patients treated with placebo.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23847363     DOI： 10.1158/2159-8290.CD-NB2013-089

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  2 in total

1.  Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group.

Authors:  AeRang Kim; Brigitte C Widemann; Mark Krailo; Nalini Jayaprakash; Elizabeth Fox; Brenda Weigel; Susan M Blaney
Journal:  Pediatr Blood Cancer       Date:  2015-04-27       Impact factor: 3.167

2.  An improved pre-clinical patient-derived liquid xenograft mouse model for acute myeloid leukemia.

Authors:  Zhisheng Her; Kylie Su Mei Yong; Kathirvel Paramasivam; Wilson Wei Sheng Tan; Xue Ying Chan; Sue Yee Tan; Min Liu; Yong Fan; Yeh Ching Linn; Kam Man Hui; Uttam Surana; Qingfeng Chen
Journal:  J Hematol Oncol       Date:  2017-10-06       Impact factor: 17.388
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.